465 related articles for article (PubMed ID: 19239382)
1. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
[TBL] [Abstract][Full Text] [Related]
2. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype.
Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S
Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500
[TBL] [Abstract][Full Text] [Related]
3. Enhanced effect of microdystrophin gene transfection by HSV-VP22 mediated intercellular protein transport.
Xiong F; Xiao S; Yu M; Li W; Zheng H; Shang Y; Peng F; Zhao C; Zhou W; Chen H; Fang L; Chamberlain JS; Zhang C
BMC Neurosci; 2007 Jul; 8():50. PubMed ID: 17617925
[TBL] [Abstract][Full Text] [Related]
4. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
Athanasopoulos T; Graham IR; Foster H; Dickson G
Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
Takeshima Y; Yagi M; Wada H; Matsuo M
Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
[TBL] [Abstract][Full Text] [Related]
6. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.
Harper SQ; Hauser MA; DelloRusso C; Duan D; Crawford RW; Phelps SF; Harper HA; Robinson AS; Engelhardt JF; Brooks SV; Chamberlain JS
Nat Med; 2002 Mar; 8(3):253-61. PubMed ID: 11875496
[TBL] [Abstract][Full Text] [Related]
7. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
[TBL] [Abstract][Full Text] [Related]
8. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy.
Lai Y; Li D; Yue Y; Duan D
Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629
[TBL] [Abstract][Full Text] [Related]
9. Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.
Athanasopoulos T; Foster H; Foster K; Dickson G
Methods Mol Biol; 2011; 709():21-37. PubMed ID: 21194019
[TBL] [Abstract][Full Text] [Related]
10. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
[TBL] [Abstract][Full Text] [Related]
11. [Adeno-associated virus vector carrying human minidystrophin gene SMCKA3999 effectively ameliorates dystrophic pathology in mdx model mice].
Li HH; Zhang SM; Fang SY; Chen CL; Luo YD; Guan Y; Wang DW; Xiao X
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1513-6. PubMed ID: 14521733
[TBL] [Abstract][Full Text] [Related]
12. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
[TBL] [Abstract][Full Text] [Related]
13. Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
Williams JH; Sirsi SR; Latta DR; Lutz GJ
Mol Ther; 2006 Jul; 14(1):88-96. PubMed ID: 16488666
[TBL] [Abstract][Full Text] [Related]
14. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
[TBL] [Abstract][Full Text] [Related]
15. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
16. [Construction of recombinant plasmid pVAX1-microdystrophin and preliminary study on the treatment to Duchenne muscular dystrophy].
Xiong F; Zhang C; Zheng H; Xiao S; Yu M; Xu Y; Liu Z; Zhou C
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):624-8. PubMed ID: 19065517
[TBL] [Abstract][Full Text] [Related]
17. Induced dystrophin exon skipping in human muscle explants.
McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.
McClorey G; Moulton HM; Iversen PL; Fletcher S; Wilton SD
Gene Ther; 2006 Oct; 13(19):1373-81. PubMed ID: 16724091
[TBL] [Abstract][Full Text] [Related]
19. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
20. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability.
Gonçalves MA; van Nierop GP; Tijssen MR; Lefesvre P; Knaän-Shanzer S; van der Velde I; van Bekkum DW; Valerio D; de Vries AA
J Virol; 2005 Mar; 79(5):3146-62. PubMed ID: 15709034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
